Sinopharm Capital contributed to a series A-plus round raised two months after ABM began enrolling patients for a phase 1 trial of its cancer drug candidate.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Müller Medien-backed telehealth diagnostics system developer raised $10.3m in a round co-led by Heal Capital and the European Bank for Reconstruction and Development.

Cyberdyne's CEJ Capital unit chipped into a round for the flu diagnostics device developer that hiked its overall funding to $27.5m.

A consortium of 15 startups were chosen to take part in the first edition of the internet technology group’s regional accelerator scheme, which will run until November this year.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from UT Southwestern with $30m.

Osage University Partners backed a round for Aerovate Therapeutics that will go to testing an inhaled version of the latter's pulmonary disease therapy.

Gene therapy developer Freeline Therapeutics priced an upsized offering at the top of its range following $275m in funding from investors including Novo.

Koch Industries and CK Hutchison both participated in a series D round that pushed the medical imaging system developer's total funding to more than $124m.